GlassScriptPhysician profile
Lynn B Geick
NPI 1326010299
$670.91
in general payments reported to CMS, 2019-2025
16 companies · $45.89 in 2025
The $45.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $76.30 · 2022: $38.40 · 2023: $41.21 · 2024: $41.69 · 2025: $45.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.13 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $108.65 | 2019 | |
| Novo Nordisk INC | $104.96 | 2019-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.84 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $56.18 | 2019-2020 | |
| Glaxosmithkline, LLC. | $41.98 | 2019 | |
| Amgen INC. | $35.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.36 | 2019 | |
| Dexcom, INC. | $17.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.89 | 2019 | |
| Astellas Pharma US INC | $12.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.89 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Geick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.